DCGI approves India's first cervical cancer vaccine HPV
The Drugs Controller General of.India (DGCI) has recently approved the Serum Institute of India (SII)
for manufacturing and marketing an anti-cervical cancer vaccine. It is India's first quadrivalent Human
Papillomavirus Vaccine (qHPV) designed to protect women from cervical cancer.
Cervical Cancer
Cervical cancer is a common.sexually transmitted infection. This is a type of cancer that occurs in the cells of the cervix, the lower.part of the uterus that connects to the vagina. This is mostly due to chronic infection with particular forms of HPV.
It is the second most prevalent cancer form and the second leading cause of cancer death among women of reproductive age (15–44).
According to the International Agency for Research on Cancer, India ranks fifth in the world with 1.23 lakh cases and approximately 67,000 deaths each year.